Aimovig

RSS

erenumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month.

Aimovig contains the active substance erenumab.

This EPAR was last updated on 02/03/2023

Authorisation details

Product details
Name
Aimovig
Agency product number
EMEA/H/C/004447
Active substance
erenumab
International non-proprietary name (INN) or common name
erenumab
Therapeutic area (MeSH)
Migraine Disorders
Anatomical therapeutic chemical (ATC) code
N02CD01
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
26/07/2018
Contact address

Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

Product information

20/02/2023 Aimovig - EMEA/H/C/004447 - R/0024

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Analgesics

Therapeutic indication

Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.

Assessment history

Related content

How useful was this page?

Add your rating
Average
6 ratings
1 rating
1 rating
2 ratings
4 ratings